Observational Study
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Dec 15, 2022; 14(12): 2380-2392
Published online Dec 15, 2022. doi: 10.4251/wjgo.v14.i12.2380
Table 3 Univariate and multivariable analyses of overall survival of hepatocellular carcinoma patients
Univariate cox regression
Multivariate logistic regression
HR
[0.025
0.975]
P
HR
[0.025
0.975]
P
Age, yr1.0201.0001.0300.0101.021.001.030.01
Gender1.5701.0302.3900.0301.420.892.260.14
HBsAg-positive1.6001.0302.4900.0401.320.822.120.25
AFP1.1000.8301.4600.500
CEA0.7600.4601.2700.300
CA1250.5800.2801.2200.150
CA19-90.6300.4200.9500.0300.650.411.030.07
ALT, U/L1.1210.4531.9760.430
AST, U/L1.3420.8762.0140.540
FIB-4 score1.0120.5471.7430.720
Liver cirrhosis1.1120.5631.9560.550
Tumor size x1.0801.0101.1600.0400.960.851.090.56
Tumor size y1.0901.0201.1700.0101.171.021.330.02
Gray-scale echogenicity0.8300.6701.0200.0800.770.600.990.04
Arterial phase enhancement0.6800.4201.1100.130
Portal phase enhancement1.2700.9901.6200.0601.250.951.630.11
Portal phase Enhancement1.1300.8101.5800.460
Enhancing capsules1.1100.7201.7100.630
Satellite nodules1.1900.7801.8300.420
Unsmooth margins0.7200.5200.9900.0400.790.561.130.19
Early reoccurrence1.2900.9901.6800.0601.250.931.670.14
Retreatment after recurrence0.7100.5401.1600.300
DLR3.2402.6703.930< 0.005